Vanguard Global Advisers »

Context Therapeutics shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Context Therapeutics (CNTX) shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Context Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Context Therapeutics held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Context Therapeutics by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $33k 13k 2.62

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Context Therapeutics

MPM Oncology Impact Management
Blue Owl Capital Holdings
Nextech Invest
Deep Track Capital
Soleus Capital Management
Octagon Capital Advisors
Avidity Partners Management
Franklin Resources
Vanguard Group
Vanguard Capital Management
TCG Crossover Management
Marshall Wace
Dr. Jeffrey R. Jay, M.D.
Millennium Management
Sio Capital Management

View all funds holding Context Therapeutics